Literature DB >> 31491470

Pediatric drug development in China: Reforms and challenges.

Weijia Wu1, Zhijia Tang2, Jiyuan Chen2, Yuan Gao3.   

Abstract

In China, child and adolescent pediatricians often face challenges in treating children with the appropriate medications. Within the last 8 years, the Chinese government has already initiated a series of policies to promote development of age-appropriate medicines for children. In this study,we introduced the current status of pediatric drugs, obstacles for pediatric drugs development and regulatory reforms in China. The lack of label information in drugs for children, inadequacy of age-appropriate dosage forms and strengths, and shortage of pediatric drugs are some of the problems commonly faced. There exists neither mandatory requirements nor enough financial drivers for development of pediatric medicines. Though some progress in terms of pediatric drugs development as well as distribution have been made by Chinese government over past years, further efforts are necessary to improve availability of pediatric medications.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  NMPA; Pediatric drug development; Pediatric study; Pediatric trial networks; Regulatory framework

Mesh:

Substances:

Year:  2019        PMID: 31491470     DOI: 10.1016/j.phrs.2019.104412

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  5 in total

1.  Recommendations on Off-Label Drug Use in Pediatric Guidelines.

Authors:  Min Meng; Qi Zhou; Wenjuan Lei; Min Tian; Ping Wang; Yunlan Liu; Yajia Sun; Yaolong Chen; Qiu Li
Journal:  Front Pharmacol       Date:  2022-06-09       Impact factor: 5.988

2.  The best pharmaceuticals for children-what can we do?

Authors:  Hao Li; Fang-Hong Shi; Shi-Ying Huang; Shun-Guo Zhang; Hui-Wen Chen
Journal:  Transl Pediatr       Date:  2020-04

3.  Disparities in economic burden for children with leukemia insured by resident basic medical insurance: evidence from real-world data 2015-2019 in Guangdong, China.

Authors:  Chunwang Zhan; Zhiming Wu; Lihua Yang; Lihua Yu; Jie Deng; Kiuco Luk; Chongyang Duan; Luwen Zhang
Journal:  BMC Health Serv Res       Date:  2022-02-19       Impact factor: 2.655

4.  Current situation of pediatric clinical trials in China: focus on trials for drug marketing application and administrative approval.

Authors:  Lin Song; Yuntao Jia; Sujuan Ran; Bin Li; Jin Xu; Bennian Huo; Nange Yin; Maolin Ai; Yao Liu
Journal:  BMC Pediatr       Date:  2022-03-18       Impact factor: 2.125

5.  Guideline for the management of pediatric off-label use of drugs in China (2021).

Authors:  Min Meng; Enmei Liu; Bo Zhang; Quan Lu; Xiaobo Zhang; Bin Ge; Ye Wu; Li Wang; Mo Wang; Zhengxiu Luo; Ziyu Hua; Xiaoling Wang; Wei Zhao; Yi Zheng; Xinan Wu; Ruiling Zhao; Wenbo Meng; Li Xiang; Gang Wang; Yuntao Jia; Yongchuan Chen; Xiaoyan Dong; Lina Hao; Chengjun Liu; Meng Lv; Xufei Luo; Yunlan Liu; Quan Shen; Wenjuan Lei; Ping Wang; Yajia Sun; Juanjuan Zhang; Ling Wang; Ruobing Lei; Tianchun Hou; Bo Yang; Qiu Li; Yaolong Chen
Journal:  BMC Pediatr       Date:  2022-07-23       Impact factor: 2.567

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.